Results 121 to 130 of about 3,398 (179)

Risk of Hypophosphatemia Following Postpartum Anemia Treatment with IV Ferric Carboxymaltose, IV Ferric Derisomaltose, and Oral Ferrous Sulfate. [PDF]

J Clin Med
Tavčar LB, Lučovnik M, Hrobat H, Gornik L, Preložnik Zupan I.   +4 more
europepmc   +1 more source

Distinct roles of ferric carboxymaltose and ferric derisomaltose on phosphate homeostasis in iron deficiency anemia. [PDF]

Eur J Pharm Sci
Dominguez Rieg JA, Domenech Acevedo M, Nogueira Coelho J, Stevens M, Thomas L, Rieg T.   +5 more
europepmc   +1 more source

Intravenous ferric carboxymaltose in patients with heart failure and iron deficiency: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. [PDF]

ESC Heart Fail
Ahmed M, Zulfiqar E, Hashmi TM, Zia R, Ashraf H, Naveed MA, Ahmed R, Rana JS, Ahmed F, Greene SJ, Fudim M, Mentz RJ, Fonarow GC.   +12 more
europepmc   +1 more source

Iron overload induced by ferric derisomaltose and ferric carboxymaltose both increase FGF-23 levels and lead to osteomalacia and bone loss in normal mice. [PDF]

Biometals
Le-Phuoc XT, Passin V, Ledesma-Colunga MG, Weidner H, Fiedler I, Busse B, Baschant U, Hofbauer LC, Rauner M.   +8 more
europepmc   +1 more source

Effectiveness and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Prospective Study in Rural and Tribal India. [PDF]

Int J Appl Basic Med Res
Sali M, Sali D, Varpe A, Kulkarni K, Gundu S, Suryawanshi S.   +5 more
europepmc   +1 more source

Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes. [PDF]

Eur J Heart Fail
Karakas M, Friede T, Butler J, Talha KM, Placzek M, Asendorf T, Diek M, Nosko A, Stas A, Kluge S, Jarczak D, DeHeer G, Rybczynski M, Bayes-Genis A, Böhm M, Coats AJS, Edelmann F, Filippatos G, Hasenfuß G, Haverkamp W, Lainscak M, Landmesser U, Macdougall IC, Merkely B, Pieske BM, Pinto FJ, Rassaf T, Visser-Rogers JK, Rosano G, Volterrani M, von Haehling S, Anker MS, Doehner W, Ince H, Koehler F, Savarese G, Khan MS, Kröhnert UR, Gori T, Trenkwalder T, Akin I, Paitazoglou C, Kobielusz-Gembala I, Kuthi L, Frey N, Licka M, Kääb S, Laugwitz KL, Ponikowski P, Anker SD.   +49 more
europepmc   +1 more source

Computational Prediction of Tissue Iron Dynamics in Iron Deficiency Anemia Following Intravenous Ferric Carboxymaltose Therapy. [PDF]

Int J Nanomedicine
Cao K, Fan X, Lee CF, Wong RSM, Chan DKL, Yan X.   +5 more
europepmc   +1 more source

Changes in Cardiac Function and Exercise Capacity Following Ferric Carboxymaltose Administration in HFrEF Patients with Iron Deficiency. [PDF]

Diagnostics (Basel)
Tsarouchas A, Bakogiannis C, Mouselimis D, Papadopoulos CE, Theofillogiannakos EK, Pagourelias ED, Kelemanis I, Boulmpou A, Antoniadis AP, Fragakis N, Efthimiadis G, Karamitsos TD, Vassilikos VP.   +12 more
europepmc   +1 more source

Intravenous Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia During Pregnancy: Effects on Maternal and Fetal Wellbeing-A Multicenter Retrospective Observational Study. [PDF]

Nutrients
Romani E, Zullino S, Speciale AR, Villa PM, Bonaldo V, Parisi F, Lubrano C, Petraglia F, Cetin I, Mecacci F.   +9 more
europepmc   +1 more source

Ferric carboxymaltose is safe and more effective than oral iron for patients with decompensated cirrhosis and iron deficiency anemia, and demonstrates circulatory, renal and prognostic benefits. [PDF]

Ann Gastroenterol
Tsiakas I, Koustousi C, Despotis G, Biros D, Tsiouris S, Lakkas L, Konstantopoulou R, Christodoulou D, Milionis H, Kalambokis GN.   +9 more
europepmc   +1 more source